DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.

Item

http://www.wikidata.org/entity/Q45395504

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.

@en

DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.

@nl

type

Item

label

DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.

@en

DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.

@nl

prefLabel

DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.

@en

DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.

@nl

P1476

DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.

@en

P2093

Chul Won Jung

http://www.w3.org/2001/XMLSchema#string

Jun Ho Jang

http://www.w3.org/2001/XMLSchema#string

Kihyun Kim

http://www.w3.org/2001/XMLSchema#string

Seok Jin Kim

http://www.w3.org/2001/XMLSchema#string

Silvia Park

http://www.w3.org/2001/XMLSchema#string

Su Jin Lee

http://www.w3.org/2001/XMLSchema#string

Won Seog Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

P304

99-105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-013-1952-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24240976

http://www.w3.org/2001/XMLSchema#string